JPMorgan maintains Johnson & Johnson (JNJ.US) “neutral” rating: Two new anti-cancer drugs show impressive data, but valuation premium limits upside potential

Zhihu Finance APP noted that the annual meeting of the European Society for Medical Oncology (ESMO) has just concluded. This is one of the most important academic conferences in the global oncology field, and the data released at the event often directly impacts the stock prices and pipeline expectations of related pharmaceutical companies. Johnson & Johnson (JNJ.US) became one of the most closely watched companies in the large pharmaceutical sector. According to a research report released by JPMorgan on October 25, the early-stage data disclosed by Johnson & Johnson for prostate cancer and head and neck cancer indications provides its innovative drug pipeline with potential differentiated competitiveness.